A RANDOMIZED PHASE II STUDY OF TWO SCHEDULES OF DECITABINE FOR FRONTLINE THERAPY OF OLDER OR UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
The goal of this clinical research study is to compare how well 2 different dosing schedules of decitabine may help control AML. Decitabine is designed to damage the DNA (the genetic material) of cells, which may cause cancer cells to die.
Treatment Location: N/A
IRB Review and Approval Date: 02/05/2013
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: